H3 Biomedicine introduces cancer research and development operations in Cambridge

H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients’ cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.

Eisai’s relationship with H3 Biomedicine also strengthens Eisai’s commitment to advancing human health care through the development of medicines to treat unmet medical needs. "Our alliance with H3 Biomedicine represents a new approach to cancer drug discovery that holds enormous promise to help patients worldwide suffering from cancer," said Haruo Naito, President and CEO of Eisai Co., Ltd.

Kentaro Yoshimatsu, PhD, who serves as Chief Scientific Officer of Eisai Product Creation Systems, will take on the additional role of President of H3 Biomedicine. In this capacity, Dr. Yoshimatsu will ensure that H3 Biomedicine’s unique business model is positioned for success while a search is conducted to identify a world-class leader to serve as Chief Scientific Officer of H3 Biomedicine.

In addition to its unique business model, the establishment of H3 Biomedicine represents a new paradigm for cancer drug discovery in which the ability to understand cancer genomes, coupled with advances in small-molecule science will serve as the foundation for creating the next generation of oncology treatments. H3 Biomedicine will follow a disciplined approach to drug discovery, relating the genetics of specific cancers to their unique vulnerabilities, and developing drugs that target those vulnerabilities. Using biomarkers to guide clinical development, H3 Biomedicine intends to enable the practice of personalized medicine for oncology patients. This biomarker-driven model for drug development is also expected to shorten clinical development timelines and reduce clinical trial costs.

According to the World Health Organization, cancer is the leading cause of death worldwide, accounting for 7.9 million deaths in 2007. Death from cancer is projected to rise, with an estimated 12 million deaths expected in 2030.

Source: H3 Biomedicine Inc

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s